A 2022 inventory in oncology news

被引：2
|
作者：
Bay, Jacques-Olivier [1 ]
Bouleuc, Carole [2 ,3 ]
Caux, Christophe [4 ]
Delom, Frederic [5 ]
Firmin, Nelly [6 ]
Gandemer, Virginie [7 ]
L'Allemain, Gilles [8 ]
Magne, Nicolas [9 ]
Orbach, Daniel [10 ]
Robert, Jacques [11 ]
Rodrigues, Manuel [12 ]
Sabatier, Renaud [13 ]
Thiery-Vuillemin, Antoine [14 ,15 ]
Wislez, Marie [16 ]
机构：
[1] CHU Clermont Ferrand, Serv Therapie Cellulaire & Hematol Clin Adulte, CHELTER UE7453, Inserm CIC 501, Site Estaing, F-63000 Clermont Ferrand, France
[2] Sorbonne Univ, Paris, France
[3] Inst Curie, Dept Soins Support, 26 Rue Ulm, F-75005 Paris, France
[4] Univ Claude Bernard Lyon 1, CNRS 5286, Ctr Rech Cancerol Lyon, Inserm U1052, F-69008 Lyon, France
[5] Univ Bordeaux, ARTiSt Lab, Inserm U1312, F-33000 Bordeaux, France
[6] Univ Montpellier, ICM Montpellier, IRCM, Inserm U1194, 208 Ave Apothicaires, F-34298 Montpellier, France
[7] CHU Rennes, Serv Hematooncol Pediat, F-35000 Rednnes, France
[8] Univ Cote Azur, CNRS, Inst Biol Valrose, Inserm, F-06108 Nice, France
[9] Inst Bergonie, Dept Radiotherapie, Bordeaux, France
[10] PSL Univ, Inst Curie, Ctr Integre Soins & Rech Oncol Enfant Adolescent, 26 Rue Ulm, F-75005 Paris, France
[11] Univ Bordeaux, Inserm U1218, F-33000 Bordeaux, France
[12] PSL Res Univ, Inst Curie, Dept Oncol Med, F-75005 Paris, France
[13] Aix Marseille Univ, CNRS, Inst Paoli Calmettes, Dept Oncol Med,Inserm, Marseille, France
[14] CHRU Jean Minjoz, Dept Med Oncol, F-25030 Besancon, France
[15] Univ Franche Comte, SFR IBCT, Inserm U1098, F-25020 Besancon, France
[16] Hop Cochin, AP HP Ctr, Serv Pneumol, Unite Oncol Thorac, F-75000 Paris, France
来源：
BULLETIN DU CANCER | 2023年 / 110卷 / 01期
关键词：
New treatments in oncology; Updates in 2022; ADJUVANT PEMBROLIZUMAB; NEOANTIGEN VACCINE; CLINICAL-TRIALS; OPEN-LABEL; STAGE-III; PHASE-III; CELL; NIVOLUMAB; PLACEBO; CHEMOTHERAPY;
D O I：
10.1016/j.bulcan.2022.12.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The Cancer Bulletin continues its tradition. At the beginning of 2023, the members of the editorial committee would like to share with you their analyses of the highlights of 2022. The objective remains to highlight what will change our practices and lead to different diagnostic or therapeutic options. Our synthesis will therefore focus on published data. They have been analyzed and placed in the more general context of the management of each type of cancer to deduce the practical consequences for our patients. This synthesis exercise will concern almost all tumor pathologies, most often on the therapeutic level, and will, however, exclude the evolution of techniques, whether they are diagnostic or used for the follow-up of our patients. The final objective is to allow you to have a thoughtful, didactic and practical reading. Our goal is to provide our readers with the rational bases that can lead to a different approach for treatments in 2023.
引用
收藏
页码：19 / 31
页数：13
相关论文
共 50 条
12345